Tao Wang

发表

Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden

M. Liedtke, H. Kantarjian, E. Jabbour, 2020, Blood Cancer Journal.

Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial.

M. Liedtke, H. Kantarjian, G. Martinelli, 2019, Leukemia research.

Camrelizumab in different PD-L1 expression cohorts of pre-treated advanced or metastatic non-small cell lung cancer: a phase II study

Ying Cheng, Yi-long Wu, Jin-Ji Yang, 2021, Cancer Immunology, Immunotherapy.

Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: A prospective, single-arm, phase II study (TD-NICE).

Xiaolong Yan, Lijun Huang, Q. Lu, 2022, International journal of surgery.

Neoadjuvant PD-1 Inhibitor combines with Chemotherapy in Resectable Squamous Cell Non-Small Cell Lung Cancer

D. Lin, J. Zhang, Shaolei Li, 2020 .

Dacomitinib (daco) versus gefitinib (gef) for first-line treatment of advanced NSCLC (ARCHER 1050): Final overall survival (OS) analysis.

Ying Cheng, T. Mok, R. Rosell, 2018 .

Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic Leukemia.

H. Kantarjian, W. Stock, D. DeAngelo, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Management of common adverse events related to first-line dacomitinib use in EGFR mutation-positive non-small-cell lung cancer: a pooled safety analysis.

T. Mok, Yi-long Wu, K. Nakagawa, 2019, Future oncology.

Time to First Subsequent Salvage Therapy in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia Treated With Inotuzumab Ozogamicin in the Phase III INO-VATE Trial.

E. Jabbour, D. DeAngelo, A. Advani, 2022, Clinical lymphoma, myeloma & leukemia.

Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO‐VATE

M. Liedtke, H. Kantarjian, E. Jabbour, 2018, Cancer.

Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22

H. Kantarjian, E. Jabbour, W. Stock, 2021, Clinical Cancer Research.

ATR Inhibitors in Platinum-Resistant Ovarian Cancer

Mingjun Zhang, Tao Wang, Siyu Li, 2022, Cancers.

Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.

Ying Cheng, T. Mok, Yi-long Wu, 2017, The Lancet. Oncology.

Impact of Tumour Hypoxia on Evofosfamide Sensitivity in Head and Neck Squamous Cell Carcinoma Patient-Derived Xenograft Models

W. Wilson, S. Jamieson, T. Lee, 2019, Cells.

Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.

M. Liedtke, H. Kantarjian, G. Martinelli, 2016, The New England journal of medicine.

Combination chemotherapy regimen with floxuridine, dactinomycin, etoposide, and vincristine as primary treatment for gestational trophoblastic neoplasia.

Y. Xiang, F. Feng, Tao Wang, 2014, Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae.

Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long‐term survival follow‐up from the randomized, phase 3 INO‐VATE study

M. Liedtke, H. Kantarjian, E. Jabbour, 2019, Cancer.

Effects of dose modifications on the safety and efficacy of dacomitinib for EGFR mutation-positive non-small-cell lung cancer.

T. Mok, Yi-long Wu, Weiwei Tan, 2019, Future oncology.

Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.

Xiangdong Zhou, Maria Rita Migliorino, Kazuhiko Nakagawa, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase I Clinical Trial and Independent Patient-Derived Xenograft Study of Combined Targeted Treatment with Dacomitinib and Figitumumab in Advanced Solid Tumors

M. Hidalgo, A. Tolcher, J. Soria, 2016, Clinical Cancer Research.

Neoadjuvant PD‐1 inhibitor combines with chemotherapy versus neoadjuvant chemotherapy in resectable squamous cell carcinoma of the lung

J Zhang, D. Lin, Shaolei Li, 2021, Thoracic cancer.

Dacomitinib versus gefitinib for the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer (ARCHER 1050): A randomized, open-label phase III trial.

Ying Cheng, T. Mok, Yi-long Wu, 2017 .

Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin

M. Liedtke, H. Kantarjian, G. Martinelli, 2019, American journal of hematology.

[The comparative study of the effects between modified FLAG and CAG on relapsed or refractory acute myeloid leukemia].

R. Gong, W. Tian, Liang-ming Ma, 2014, Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi.

Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome–positive relapsed/refractory acute lymphoblastic leukemia

M. Liedtke, H. Kantarjian, G. Martinelli, 2020, Cancer.

Phase II Randomized Study of Figitumumab plus Docetaxel and Docetaxel Alone with Crossover for Metastatic Castration-Resistant Prostate Cancer

F. Saad, H. Pandha, D. Petrylak, 2014, Clinical Cancer Research.

Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial.

W. Feng, Xiaoqing Liu, Yunpeng Liu, 2019, The Lancet. Respiratory medicine.

Extensive safety profile of inotuzumab ozogamicin (InO) in relapsed/refractory acute lymphoblastic leukemia (ALL) patients enrolled in the phase 3 INO-VATE trial.

M. Liedtke, H. Kantarjian, G. Martinelli, 2018 .

Inotuzumab Ozogamicin (InO) Vs Standard of Care (SC) in Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL): Long-Term Results of the Phase 3 INO-VATE Study

M. Liedtke, H. Kantarjian, E. Jabbour, 2017 .

Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the Global Phase 3 INO-VATE Trial: Efficacy and Safety By Baseline CD22 Expression Level

H. Kantarjian, E. Jabbour, W. Stock, 2017 .

Inotuzumab Ozogamicin (InO) for Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL) in the Global Phase 3 INO-VATE Trial: Efficacy By MLL Status

M. Liedtke, H. Kantarjian, E. Jabbour, 2017 .

Inotuzumab Ozogamicin Versus Standard of Care for Relapsed/Refractory Acute Lymphoblastic Leukemia in the Phase 3 Randomized INO-Vate Trial: Outcomes By Salvage Treatment Phase

M. Liedtke, H. Kantarjian, E. Jabbour, 2016 .

Efficacy and safety of inotuzumab ozogamicin (InO) in older patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) enrolled in the phase 3 INO-VATE trial.

M. Liedtke, H. Kantarjian, G. Martinelli, 2016 .

Impact of number of cycles on outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicin

H. Kantarjian, E. Jabbour, W. Stock, 2020, British journal of haematology.

Impact of minimal residual disease (MRD) status in clinical outcomes of patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) treated with inotuzumab ozogamicin (InO) in the phase 3 INO-VATE trial.

M. Liedtke, H. Kantarjian, G. Martinelli, 2018 .

Inotuzumab ozogamicin (InO) for relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) in the phase III INO-VATE trial: Efficacy and safety by prior therapy.

M. Liedtke, H. Kantarjian, G. Martinelli, 2016 .

Impact of salvage treatment phase on inotuzumab ozogamicin treatment for relapsed/refractory acute lymphoblastic leukemia: an update from the INO-VATE final study database

H. Kantarjian, E. Jabbour, W. Stock, 2020, Leukemia & lymphoma.

Efficacy and Safety Outcomes in the Phase 3 INO-Vate Trial By Baseline CD22 Positivity Assessed By Local Laboratories

H. Kantarjian, E. Jabbour, W. Stock, 2019, Blood.

Preoperative chemotherapy combined with PD-1 inhibitor in locally advanced operable or potentially resectable esophageal squamous cell carcinoma: A real world study.

Jia Wei, Baorui Liu, Lifeng Wang, 2021, Journal of Clinical Oncology.

INTRIGUE: A phase III, randomized, open-label study to evaluate the efficacy and safety of ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib

Robin L. Jones, J. Blay, Yoon-Koo Kang, 2022, Journal of Clinical Oncology.

Prophylactic doxycycline (doxy) lessens rash from dacomitinib (D) an EGFR inhibitor with no rash or diarrhea improvement from corticosteroids or probiotics.

M. Lacouture, A. Jatoi, S. Sonis, 2015 .

ALK-R3HDM1 and EML4-ALK fusion as a mechanism of acquired resistance to gefitinib: A case report and literature review

Yuehong Wang, Tao Wang, Zhu Zeng, 2022, Frontiers in Oncology.

Impact of a planned dose interruption of dacomitinib in the treatment of advanced non-small-cell lung cancer (ARCHER 1042).

M. Lacouture, Dong-Wan Kim, B. Cho, 2017, Lung cancer.

Phase II trial of the irreversible oral pan-HER inhibitor PF-00299804 (PF) as first-line treatment in recurrent and/or metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN).

L. Siu, Siddharth Singh, S. Chia, 2010 .